Novartis Japan faces penalty over drug side effects
Tokyo
JAPANESE health authorities said on Wednesday that they will soon make a decision on a possible penalty against the local unit of Swiss pharmaceutical giant Novartis for failing to report drug side effects.
That followed media reports which said regulators would slap a 15-day suspension order on the firm, meaning the company could not sell most of its drugs during the two-week period - a first for a pharmaceutical firm operating in Japan.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share